Guggenheim Maintains Buy on IGM Biosciences, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Guggenheim has maintained its Buy rating on IGM Biosciences but has lowered the price target from $25 to $20.
October 01, 2024 | 5:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Guggenheim has maintained its Buy rating on IGM Biosciences but has lowered the price target from $25 to $20.
The maintenance of a Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates a more cautious outlook on its valuation. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100